Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Infections 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 9Ciprofloxacin 8Voriconazole 5Vancomycin 4Caspofungin 4Amoxicillin-Potassium Clavulanate Combination 4gamma-Globulins 3Fluconazole 3Filgrastim 3Daptomycin 3Antibiotic Prophylaxis 3plerixafor 2liposomal amphotericin B 2Whole-Body Irradiation 2Trimethoprim 2Therapeutics 2Sulfamethoxazole 2Saline Solution 2Ribavirin 2Polymerase Chain Reaction 2Piperacillin, Tazobactam Drug Combination 2Peripheral Blood Stem Cell Transplantation 2Pentetic Acid 2Moxifloxacin 2Melphalan 2Levofloxacin 2Lenalidomide 2Itraconazole 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infections × telaprevir × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡